AZN vs JNJ
AstraZeneca PLC and Johnson & Johnson, both Healthcare
Johnson & Johnson is the larger company at $635B against $266B. Over the past year JNJ returned +40% against +3.4% for AZN. The RyuScore puts JNJ ahead, 68 against 62 out of 100.
| Figure | AZN | JNJ |
|---|---|---|
| Last close | $171 | $264 |
| Market cap | $266B | $635B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 40.0 |
| Dividend yield | n/a | 2.0% |
| 1-year return | +3.4% | +40% |
| 5-year return | +55% | +88% |
| RyuScoresector-relative, 1–10 | 62/100 | 68/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Johnson & Johnson
Revenue of $25B in Q3 2026, net income $210M. Its largest reported line is DARZALEX, 19% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.